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Abstract
Background: This study was designed to explore the feasibility, safety, and outcomes of pre-
operative oxaliplatin-dacarbazine combination therapy for the treatment of advanced soft tissue
sarcoma (STS) of the limb.
Patients and Methods: Between November 2005 and November 2008, 31 patients with
advanced limb STS classified with stage IV STS were randomly assigned into experimental or
control groups, and both were given 2 cycles of chemotherapy before undergoing surgery. The
regimen for the experimental group was oxaliplatin (120 mg/m2, d1) in combination with
dacarbazine (175 mg/m2, d13), while that for the control group was a standard vincristine,
epirubicin, cyclophosphamide therapy. Operations were carried out four weeks after the second
chemotherapy cycle, followed by another 24 more chemotherapy cycles of the previous regimen.
Results: Following preoperative chemotherapy, the experimental group exhibited a significant
improvement in tumor regression compared to controls. Both regimens were well-tolerated, and
no significant differences in adverse reactions were noted. At a median follow-up of 24 months, 28
patients were still alive and had normal limb function. The progression free survival rate of the
experimental group was significantly higher than that of the control group (10/15 vs. 4/16, p < 0.05).
Conclusion:  Oxaliplatin- dacarbazine neoadjuvant/adjuvant chemotherapy improved the
prognosis of patients with advanced limb STS in comparison with vincristine, epirubicin,
cyclophosphamide combination therapy.
Background
Soft Tissue Sarcomas (STS) are malignant tumors that
develop within mesenchymal connective tissue and can
occur in any part of the body, most commonly in the
limbs, which represent over 45% of occurrences [1]. STS
growth does not usually cause any noticeable symptoms
in early stages, making early detection uncommon. Some
STS such as synovial sarcoma, malignant fibrous histiocy-
toma, rhabdomyosarcoma and certain neurogenic sarco-
mas tend to invade peripheral tissues, such as nerves,
vessels and bones, and are thus have a relatively poor
prognosis and are difficult to cure [2].
The treatment of limb STS have traditionally included sur-
gery, which can involve extensive muscle excision or resec-
tion [3]. Amputation is not an ideal treatment measure,
and is generally opted for only when other treatment has
proven unsuccessful [4]. For advanced limb STSs with
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large tumor mass, distinct local infiltration or post-surgi-
cal relapse, chemotherapy or radiotherapy combined with
surgery is often the first choice [5-7]. Apart from reducing
tumor volume, chemotherapy before surgery can also pro-
duce a reaction zone between the tumor and peripheral
tissues, which serves as an operational tissue space for sur-
gery. However, it remains unclear whether comprehensive
treatment schemes using novel chemotherapy regimens
could improve the treatment results and prognoses for
advanced limb STS [8]. In the present study, we compared
pre-operative chemotherapy with oxaliplatin and dacar-
bazine to the traditional pre-operative VAC treatment,
with the hopes of determining it's safety and to assess
whether this regimen imparts a greater advantage, in
terms of reducing the tumor margin and increasing pro-
gression free survival.
Patients and Methods
Inclusion Criteria
① Between 14 years and 70 years of age. ✍ Female patients
that were pregnant or lactating were excluded. ③ No his-
tory of chronic primary organ disease, heart failure or
other major organ malfunction. ④ The sarcoma originated
in limb soft tissue. ⑤ Belong to G1-3T3N0M0 or G1-3T1-
3N0-1M1, that is, stage IV according to the Russell GTNM
staging system. ⑥ No prior chemotherapy or radiation
therapy.
Patients
Between November 2005 and November 2008, the
Department of Surgical Oncology of Zhejiang Provincial
Hospital in China received and treated 31 patients with
stage IV limb STS. 15 of these were randomly assigned to
the experimental group, and the remaining 16 were
assigned to the control group. Patients aged between 18
and 66, with a median age of 41 in the experimental
group and 50 in the control group (t = -0.858, p > 0.05).
The average tumor size for each group was determined to
be in the T3 range (for infiltrating the peripheral vessel,
nerve or skeleton). The mean tumor size was 8.4 ± 2.8 cm
in the experimental group, and 7.2 ± 1.8 cm (t = 1.453, p
> 0.05). In the experimental group, two patients were
diagnosed with regional lymph node metastasis, 2 with
lung metastasis. In the control group, 3 patients were diag-
nosed with regional lymph node metastasis, and 1 with
lung metastasis in the control group, the difference in the
prevalence of metastases was not significant (χ2 = 0.011, p
> 0.05). Table 1 shows the clinical characteristics of
patients recruited for the study.
The study was conducted according to Good Clinical Prac-
tices and was approved by the local ethics committee. All
patients gave written informed consent.
Treatment Regimen
Both groups of patients were examined for contraindica-
tions to chemotherapy and surgery. Two cycles of contin-
uous intravenous chemotherapy, 28 days apart, were
administered before surgery. For the experimental group,
the treatment regimen consisted of 120 mg/m2 d1 oxalipl-
atin (L-OHP) with 175 mg/m2 d13 dacarbazine (DTIC).
The control group received standard VAC chemotherapy 1
mg/m2/d1 vincristine (VCR), 60 mg/m2 d1 epirubicin (Epi-
ADM), and 600 mg/m2 d1 cyclophosphamide (CTX). Sur-
gical procedures consisting of extensive resection or mus-
cle excision were carried out four weeks after the second
cycle, followed by another 24 cycles of chemotherapy
using the same pre-surgical treatment. Post-operative radi-
otherapy was undertaken by 3 cases in the experimental
group and 10 cases in the control group, respectively.
Endpoints and adverse reactions
The primary endpoint was progression-free survival, while
the secondary endpoints were toxicity of chemotherapy
and efficacy of chemotherapy determined by CT or MRI
before prior to surgery. Chemotherapeutic response was
evaluated using the RECIST criteria. Complete response
(CR) was defined as the disappearance of tumors (on the
basis of CT scan results) for over 4 weeks, partial response
(PR) was defined as the reduction of overall tumor vol-
Table 1: Clinical Characteristics of Patients
Experimental group (cases) Control group (cases)
Tumor location upper arm 3 3
Thigh 7 11
lower leg 5 2
Pathological phenotypes malignant fibrous histiocytoma 8 6
rhabdomyosarcoma 3 3
synovial sarcoma 0 4
malignant nerve sheath tumor 1 1
clear cell sarcoma 2 0
unclassifiable 1 2
Cytological grading G2 0 1
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ume by more than 50% for over 4 weeks, and stable dis-
ease (SD) was defined as a less than 25% reduction in
tumor volume. Chemotherapy toxicity was evaluated in
accordance with the CTCAE v3.0 issued by the NCI on
August 9, 2006.
Statistical Analyses
Chemotherapeutic response, surgical margins and thera-
peutic outcomes were compared between experimental
and control groups using Chi-square analyses. Progres-
sion free survival time of each group was compared by
Log-Rank test. The correlations between chemotherapeu-
tic regimen, chemotherapeutic response, surgical margin
and therapeutic outcomes were tested using Pearson's
multivariate correlation analyses. All statistical analyses
were performed using the SPSS11.5 Software Package.
Results
The results from the response evaluation after two cycles
of chemotherapy were as follows: 2 CR, 11 PR, and 2 SD
in the experimental group; 1 CR, 5 PR, 10 SD in the con-
trol group. The difference of response between the two
groups was found to be statistically significant (χ2 = 7.878,
p < 0.05; Table 2). The tumor response rate in the experi-
mental group was 87%, while the tumor response rate in
the control group was 38%, correspondingly. Limb-pre-
serving operations were carried out in each case of both
groups. But there were 2 cases got positive surgical margin
in the experimental group, while 10 cases got positive sur-
gical margin in the control group. Both chemotherapy reg-
imens were well-tolerated with no significant difference
between experimental and control group (χ2 = 0, p  >
0.05). In both groups, no treatment-related deaths
occurred, and all adverse reactions were below grade II.
Figure 1 shows CT scans of a representative case in the
experimental group. Table 3 shows the adverse reactions
in detail.
At the median follow-up of 24 months, 10 patients were
tumor free, sarcoma had relapsed in 4 patients and 1
patient had died in the experimental group. The only
death occurred in a patient who did not respond to the
chemotherapy and had metastases in both lungs before
surgery. In the control group, 4 patients were tumor free,
sarcoma persisted in 10 patients, and 2 patients had died.
Of the two deaths in the control group, one was found to
be with lung metastasis before surgery and died 13
months after operation, the other one suffered from lung
metastasis 3 months after operation and died 15 months
after operation. The difference of progression free survival
between the two groups was significant (χ2 = 5.427, p <
0.05; Table 2). Limb functions were essentially normal in
all the 28 patients who survived. Median progression-free
survival was significantly higher in the experimental
group (21 months) compared to the control group (19
months; Z = 4.44, p < 0.05; Figure 2). Until the end of the
follow-up, the difference in overall survival between the
two groups was not significant (Z = 0.28, p > 0.05; Figure
3).
Pearson's multivariate correlation analysis indicated sig-
nificant correlations between progression free survival
(PFS), chemotherapy regimens, chemotherapeutic
response, and surgical margin. As shown in Table 4, the
treatment given in the experimental group improved
chemotherapeutic response, reduced the positive rate of
the surgical margin and increased PFS, chemotherapeutic
response had a correlation with negative surgical margin
and PFS, and negative surgical margin had a increased
PFS.
Discussion
In this study, a combination of oxaliplatin-dacarbazine
was used as neoadjuvant/adjuvant chemotherapy, with
the intention of exploring the usefulness of this regimen
as a safe and effective treatment for advanced limb STS.
This combination chemotherapy was generally well toler-
ated and no serious adverse events were noted during or
after chemotherapy. Compared to a traditional VAC regi-
men, oxaliplatin-based chemotherapy significantly
improved prognosis over the median follow-up duration
of 24 months and improved the negative rate of surgical
margin to a greater degree in patients with stage IV limb
STS. Importantly, oxaliplatin combination therapy signif-
icantly increased progression free survival over the study
period. These results indicate that oxaliplatin-dacarbazine
chemotherapy can effectively improve tumor remission in
Table 2: Statistical Analysis of Therapeutic Response and Prognosis in the Two Groups
Experimental group (cases) Control group (cases) p value
Chemotherapy response CR 2 1 <0.05
PR 11 5
SD 2 10
Surgical margin Negative 13 6 <0.01
Positive 2 10
Progression free survival Yes 10 4 <0.05
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patients with advanced limb STS compared to traditional
VAC scheme.
Safety of the Oxaliplatin-Dacarbazine Treatment
In this study, we used a combination of oxaliplatin and
dacarbazine as neoadjuvant/adjuvant chemotherapy to
determine the safety and efficacy of this treatment for
advanced limb STS. To our knowledge, this study consti-
tutes the first report for the use of oxaliplatin in the treat-
ment of advanced STS. Previously, oxaliplatin has been
used to treat malignant tumors in the digestive system,
ovarian cancer, breast cancer, lymphoma, small cell lung
cancer, among others and its safety has been widely con-
firmed. A phase I and pharmacokinetic study of peme-
trexed in combination with oxaliplatin was ever
performed to determine the maximum tolerated dose
(MTD), and to evaluate safety and pharmacokinetics in
patients with metastatic solid tumors. Thirty-six patients
with advanced tumors were observed, including 5 patients
with sarcomas. This study demonstrated that the combi-
Table 3: Adverse Events of Chemotherapy in the Two Groups
AE Grade (CTCAEv3.0) Experimental group (cases) Control group (cases) p value
Nausea 1 (mild) 9 10 >0.05
2 (moderate) 4 5
Vomiting 1 (mild) 5 7 >0.05
2 (moderate) 1 1
Asthenia 1 (mild) 6 4 >0.05
2 (moderate) 0 0
Granulocytopenia 1 (mild) 7 8 >0.05
2 (moderate) 2 0
Anaemia 1 (mild) 2 1 >0.05
2 (moderate) 0 0
Peripheral Neuropathy 1 (mild) 12 0 Not Comparable
2 (moderate) 3 0
Image of Typical CR Case Figure 1
Image of Typical CR Case. A. Tumor before chemotherapy. B. Lung metastasis before chemotherapy. C. Tumor after 
chemotherapy. D. No mass in lung after chemotherapy.Journal of Experimental & Clinical Cancer Research 2009, 28:119 http://www.jeccr.com/content/28/1/119
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Kaplan-Meier chart for PFS Figure 2
Kaplan-Meier chart for PFS. Progression free survival curve showed that PFS of study group was superior to that of con-
trol group. "Censored" means cases without endpoint event at the end of follow-up.
Kaplan-Meier chart for OS Figure 3
Kaplan-Meier chart for OS. Survival curve showed that the difference of OS between the two groups was not significant. 
"Censored" means cases without endpoint event at the end of follow-up.Journal of Experimental & Clinical Cancer Research 2009, 28:119 http://www.jeccr.com/content/28/1/119
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nation of pemetrexed plus oxaliplatin is feasible and can
be safely administered every 21 days in patients with solid
tumors. Toxic effects were predictable, reversible and
manageable, with neutropenia being the primary toxicity
and no unexpected toxicity observed. The recommended
dosage for oxaliplatin was 120 mg/m2 [9]. Dacarbazine is
considered a critical chemotherapeutic agent in compre-
hensive treatment regimes for advanced STSs [10,11].
Patients in both the experimental and control groups
experienced grade 1 to 2 adverse effects, consisting mainly
of digestive and blood system toxicity. All patients had
mild to moderate peripheral neuropathy, which remitted
following the drug treatment, as expected from previous
studies. No severe adverse reactions occured in the exper-
imental group suggesting that oxaliplatin-dacarbazine
combination treatment is likely to be tolerable and safe
for patients with limb STS.
Oxaliplatin-based adjuvant chemotherapy for the 
treatment of advanced limb STS
Despite the small sample size of this study, our results
show a clear advantage in the use of oxaliplatin-based
neoadjuvant chemotherapy: the tumor response rate in
the experimental group was 87%, limb-preserving opera-
tions were carried out in all cases. In addition, this combi-
nation therapy may also prove beneficial for the treating
of distant metastatic tumors, this hypothesis is supported
by the fact that one patient's lung metastasis disappeared
after the first cycle of chemotherapy.
Our follow-up analysis at a median of 24 months revealed
that all patients from the experimental group who showed
significant benefits of chemotherapy before surgery were
still alive, including survivors with and without tumors.
The only death occurred in a patient who did not respond
to the chemotherapy and had metastases in both lungs
before surgery. In general, the prognoses for patients with
distant metastases were much worse, with a shorter pro-
gression-free stage. Prognoses were best for patients who
had no distant metastasis before surgery and who showed
significant chemotherapeutic response, this was similar to
observations seen in another study [12]. Patients in the
experimental group mainly benefited from tumor-free
survival, without a corresponding increase in overall sur-
vival. There was no significant difference in overall sur-
vival time between experimental and control groups,
which may reflect the short follow-up time and the small
sample size of the study. Future studies using larger
cohorts and a longer follow-up time may reveal survival
benefits. In addition, we discovered that the two CR cases
from the experimental group were both patients with neu-
rogenic tumors. Whether neurogenic tumors are more
sensitive to oxaliplatin-dacarbazine treatment is worthy of
further investigation [13].
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